Abiomed to Showcase Impella® Technology at TCT 2009; Customer Evening Symposium on Tuesday, September 22

- Customer Evening Symposium on September 22 from 7:00 – 10:00 p.m., (following the Investor and Analyst Meeting from 4:00 – 5:00 p.m., September 22)

- TCT Breakfast Session on September 23 from 6:30 – 8:00 a.m.

- TCT Breakfast Session on September 25 from 6:30 – 8:00 a.m.

• Press Release
• Source: Abiomed, Inc.
• On 11:25 am EDT, Tuesday September 8, 2009

DANVERS, Mass.--(BUSINESS WIRE)--Abiomed Inc. (NASDAQ: ABMD - News), a leading provider of breakthrough heart support technologies, today announced its schedule of events at the Cardiovascular Research Foundation's (CRF) annual Transcatheter Cardiovascular Therapeutics (TCT) scientific meeting, scheduled from September 21 - 25, in San Francisco.

Related Quotes

Symbol	Price	Change
ABMD	8.70	-0.28

{"s" : "abmd","k" : "c10,l10,p20,t10","o" : "","j" : ""}

In addition to the Abiomed-hosted investor and analyst meeting, customer symposiums, and TCT-hosted Impella presentations, Abiomed will also conduct daily booth demonstrations at Abiomed booth #1230 and hands-on simulations of its heart recovery platforms. The company will also broadcast daily live feeds of Impella cases from the TCT line-up of live case broadcasts. In addition, the Abiomed booth will feature physicians presenting challenging cases using Impella 2.5.

ABIOMED SCHEDULE OF TCT 2009 EVENTS:

MONDAY, SEPTEMBER 21

TCT PRE-CONFERENCE PRESENTATIONS
Device-Based Approaches for Heart Failure: Recent Developments and New Directions
Session V: Acute Hemodynamic Support Devices
Monday, September 21
Room 132, Moscone Convention Center

The following presentations will focus on Impella and Abiomed technology during the TCT Scientific Track: “Device-Based Approaches for Heart Failure: Recent Developments and New Directions, Session V: Acute Hemodynamic Support Devices”:

• 2:50 – 3:02 p.m. – Circulatory Support in STEMI: Intra-aortic Balloon Counterpulsation vs. Impella, presented by Jose P.S. Henriques, M.D., Ph.D., Academic Medical Center, University of Amsterdam
• 3:02 – 3:14 p.m. – The Impella 5.0 Device: Surgical and Cardiogenic Shock Applications, presented by Anson Cheung, M.D. clinical associate professor, surgical director, cardiac transplant program of BC Active Staff, St. Paul's Hospital Vancouver
• 3:14 – 3:26 p.m. – Results from USpella, the first registry presentation on the U.S. commercial Impella experience with over 100 patients, presented by Brijeshwar Maini, M.D., co-chair, cardiovascular research, interventional cardiologist, Pinnacle Health; attending cardiologist, Moffitt Heart & Vascular Group
• 3:26 – 3:38 p.m. – Continuum in Circulatory Support to Recover the Failing Heart: How and When to Escalate from Percutaneous to Surgical VADs, presented by Mark Anderson, M.D., associate professor of surgery at UMDNJ-Robert Wood Johnson Medical School and chief of the section of cardiac surgery at Robert Wood Johnson University Hospital

TUESDAY, SEPTEMBER 22

ABIOMED INVESTOR AND ANALYST MEETING
Tuesday, September 22
Room Golden Gate 4, Hilton San Francisco
4:00 - 5:00 p.m.

The Abiomed-sponsored investor and analyst meeting will be hosted by Michael R. Minogue, Chairman, Chief Executive Officer and President; Bob Bowen, Vice President, Chief Financial Officer and David Weber, Ph.D., Chief Operating Officer, who will provide a 40-minute overview and update on Impella progress. Following the prepared remarks by Abiomed management, will be a 20-minute forum for questions and open discussion. To register for the Abiomed investor and analyst meeting on Tuesday, September 22, please contact Aimee Maillett at amaillett@abiomed.com or (978) 646-1553.

ABIOMED EVENING CUSTOMER SYMPOSIUM – “Hemodynamic Principles to Patient Application”
Tuesday, September 22
Imperial Ballroom, Hilton San Francisco
7:00 - 8:00 p.m. – Cocktail reception
8:00 - 10:00 p.m. – Symposium and clinical presentations

The Abiomed-sponsored evening customer symposium is entitled, “Hemodynamic Principles to Patient Application,” chaired by William O’Neill, M.D., executive dean for clinical affairs at the University of Miami. This is a customer event and participation for non-customers is subject to availability and Abiomed discretion. Non-customers must request attendance by contacting Aimee Maillett at amaillett@abiomed.com or (978) 646-1553.

SYMPOSIUM TOPICS, SPEAKERS WILL INCLUDE:

• Science of Hemodynamics – John Lasala, M.D., Ph.D., medical director of the cardiac cath lab, associate professor of medicine and director of interventional cardiology at Barnes-Jewish Hospital
• Impella and PCI, Theory and Case – Samin Sharma, M.D., director of the cath lab and interventions, Mount Sinai Medical Center
• Impella and AMI, Theory and Case – Amsterdam, Jose P.S. Henriques, M.D., Ph.D., Academic Medical Center, University of Amsterdam
• Panel Discussion

WEDNESDAY, SEPTEMBER 23

TCT BREAKFAST SESSION – “Impella 2.5 - Case Reviews of Real World Application”
Wednesday, September 23
Room 114 A, Moscone Convention Center
6:30 – 7:00 a.m. – Breakfast
7:00 – 8:00 a.m. – Presentations

The Abiomed-sponsored TCT breakfast session will be a continuation of the Tuesday evening symposium, but focused on an audience interactive review of “Real World Impella Cases,” chaired by Charanjit S. Rihal, M.D., director of the cardiac cath lab and professor of medicine, Mayo Clinic.

BREAKFAST SESSION TOPICS, SPEAKERS WILL INCLUDE:

• Presentation – Results from USpella, the first registry presentation on the U.S. commercial Impella experience with over 100 patients will be presented by Brijeshwar Maini, co-chair, cardiovascular research, interventional cardiologist, Pinnacle Health; attending cardiologist, Moffitt Heart & Vascular Group.
• Case Reviews and Panel – Raj Dave, M.D., Pinnacle Health; Steven J. Yakubov, M.D., Riverside Methodist Hospital; Srihari Naidu, M.D., Winthrop Hospital; Mark Grise, M.D., Ochsner Medical Center; Wissam Gharib, M.D., University of West Virginia, School of Medicine

ABIOMED TCT BOOTH PRESENTATIONS ON IMPELLA 2.5 CASES
Wednesday, September 23
Abiomed TCT booth # 1230
12:30 p.m. – Ted Schreiber, M.D., Harper Hospital
Abiomed-hosted customer presentation

THURSDAY, SEPTEMBER 24

ABIOMED TCT BOOTH PRESENTATIONS ON IMPELLA 2.5 CASES
Thursday, September 24
Abiomed TCT booth # 1230
12:30 p.m. – Srihari Naidu, M.D., Winthrop Hospital
Abiomed-hosted customer presentation

FRIDAY, SEPTEMBER 25

TCT BREAKFAST SESSION – “Impella 2.5 - Hemodynamic Support in High Risk PCI and Cardiogenic Shock: A Case-Based Review”
Friday, September 25
Room 114, Moscone Convention Center
6:30 – 7:00 a.m. – Breakfast
7:00 – 8:00 a.m. – Presentations

The Abiomed-sponsored TCT breakfast session will focus on a new fellow scholarship program where fellows present their best Impella cases to their peers, called, “International Fellows Awarded Best Impella Case of the Year,” chaired by Roxana Mehran, M.D., director of outcomes research, data coordination and analysis, associate professor of medicine, New York-Presbyterian Hospital/Columbia University Medical Center and director of clinical research, data coordination and analysis center at the Cardiovascular Research Foundation.

BREAKFAST SESSION TOPICS, SPEAKERS WILL INCLUDE:

• Panel Members – Igor Palacios, M.D., director of interventional cardiology, Massachusetts General Hospital, associate professor of medicine, Harvard University; Raj Makkar, M.D., director, interventional cardiology and cardiac cath lab, Cedars-Sinai Medical Center
• The three winners of the National Fellows Awards will present at the breakfast session.

ABOUT ABIOMED

Based in Danvers, Massachusetts, Abiomed, Inc. is a leading provider of medical devices that provide circulatory support to acute heart failure patients across the continuum of care in heart recovery. Our products are designed to enable the heart to rest, heal and recover by improving blood flow and/or performing the pumping of the heart. For additional information please visit: www.abiomed.com.

FORWARD-LOOKING STATEMENTS

This Release contains forward-looking statements, including statements regarding development of Abiomed's existing and new products, the Company's progress toward commercial growth, and future opportunities. The Company's actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including uncertainties associated with development, testing and related regulatory approvals, anticipated future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological change, government regulation, future capital needs and uncertainty of additional financing, and other risks and challenges detailed in the Company's filings with the Securities and Exchange Commission, including the Annual Report filed on Form 10-K. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this Release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this Release or to reflect the occurrence of unanticipated events.

Abiomed, Impella, iPulse, BVS5000, AB5000 and the Abiomed logo are all trademarks of Abiomed. Other company and product names may be trademarks of their respective owners.

Abiomed
Aimee Maillett, 978-646-1553
Public Relations Specialist
amaillett@abiomed.com